In Section C, individuals will obtain ABBV-744 and oral navitoclax. In Segment D, individuals will receive ABBV-744 and ruxolitinib. Participants will receive treatment until ailment progression or perhaps the members are not able to tolerate the study drugs. - Participant consumed grapefruit or grapefruit items within 3 days ahead of https://juliuse433qbl5.elbloglibre.com/profile